Cargando…

Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand

OBJECTIVE: To determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer cells. EXPERIMENTAL DESIGN: The binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell lines and to normal canine bladder urothelial cells was determined...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Tzu-yin, Zhang, Hongyong, Wang, Sisi, Xie, Li, Li, Bin, Rodriguez, Carlos O, de Vere White, Ralph, Pan, Chong-xian
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040722/
https://www.ncbi.nlm.nih.gov/pubmed/21272294
http://dx.doi.org/10.1186/1476-4598-10-9
_version_ 1782198364136275968
author Lin, Tzu-yin
Zhang, Hongyong
Wang, Sisi
Xie, Li
Li, Bin
Rodriguez, Carlos O
de Vere White, Ralph
Pan, Chong-xian
author_facet Lin, Tzu-yin
Zhang, Hongyong
Wang, Sisi
Xie, Li
Li, Bin
Rodriguez, Carlos O
de Vere White, Ralph
Pan, Chong-xian
author_sort Lin, Tzu-yin
collection PubMed
description OBJECTIVE: To determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer cells. EXPERIMENTAL DESIGN: The binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell lines and to normal canine bladder urothelial cells was determined using the whole cell binding assay and an affinitofluorescence assay. The WST-8 assay was performed to determine whether PLZ4 affected cell viability. In vivo tumor-specific homing/targeting property and biodistribution of PLZ4 was performed in a mouse xenograft model via tail vein injection and was confirmed with ex vivo imaging. RESULTS: PLZ4 exhibited high affinity and specific dose-dependent binding to canine bladder TCC cell lines, but not to normal canine urothelial cells. No significant changes in cell viability or proliferation were observed upon incubation with PLZ4. The in vivo and ex vivo optical imaging study showed that, when linked with the near-infrared fluorescent dye Cy5.5, PLZ4 substantially accumulated at the canine bladder cancer foci in the mouse xenograft model as compared to the control. CONCLUSIONS AND CLINICAL RELEVANCE: PLZ4 can specifically bind to canine bladder cancer cells. This suggests that the preclinical studies of PLZ4 as a potential diagnostic and therapeutic agent can be performed in dogs with naturally occurring bladder cancer, and that PLZ4 can possibly be developed in the management of canine bladder cancer.
format Text
id pubmed-3040722
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30407222011-02-18 Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand Lin, Tzu-yin Zhang, Hongyong Wang, Sisi Xie, Li Li, Bin Rodriguez, Carlos O de Vere White, Ralph Pan, Chong-xian Mol Cancer Short Communication OBJECTIVE: To determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer cells. EXPERIMENTAL DESIGN: The binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell lines and to normal canine bladder urothelial cells was determined using the whole cell binding assay and an affinitofluorescence assay. The WST-8 assay was performed to determine whether PLZ4 affected cell viability. In vivo tumor-specific homing/targeting property and biodistribution of PLZ4 was performed in a mouse xenograft model via tail vein injection and was confirmed with ex vivo imaging. RESULTS: PLZ4 exhibited high affinity and specific dose-dependent binding to canine bladder TCC cell lines, but not to normal canine urothelial cells. No significant changes in cell viability or proliferation were observed upon incubation with PLZ4. The in vivo and ex vivo optical imaging study showed that, when linked with the near-infrared fluorescent dye Cy5.5, PLZ4 substantially accumulated at the canine bladder cancer foci in the mouse xenograft model as compared to the control. CONCLUSIONS AND CLINICAL RELEVANCE: PLZ4 can specifically bind to canine bladder cancer cells. This suggests that the preclinical studies of PLZ4 as a potential diagnostic and therapeutic agent can be performed in dogs with naturally occurring bladder cancer, and that PLZ4 can possibly be developed in the management of canine bladder cancer. BioMed Central 2011-01-27 /pmc/articles/PMC3040722/ /pubmed/21272294 http://dx.doi.org/10.1186/1476-4598-10-9 Text en Copyright ©2011 Lin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Lin, Tzu-yin
Zhang, Hongyong
Wang, Sisi
Xie, Li
Li, Bin
Rodriguez, Carlos O
de Vere White, Ralph
Pan, Chong-xian
Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
title Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
title_full Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
title_fullStr Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
title_full_unstemmed Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
title_short Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
title_sort targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040722/
https://www.ncbi.nlm.nih.gov/pubmed/21272294
http://dx.doi.org/10.1186/1476-4598-10-9
work_keys_str_mv AT lintzuyin targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand
AT zhanghongyong targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand
AT wangsisi targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand
AT xieli targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand
AT libin targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand
AT rodriguezcarloso targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand
AT deverewhiteralph targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand
AT panchongxian targetingcaninebladdertransitionalcellcarcinomawithahumanbladdercancerspecificligand